Kriya Therapeutics CEO and leadership

Shankar Ramaswamy is the Co-Founder, Chairman, and Chief Executive Officer of Kriya Therapeutics. Dr. Ramaswamy was part of the early foundational team at Roivant Sciences, where he was responsible for helping to identify and evaluate assets across therapeutic areas and launch its first public subsidiary company. He went on to be the Chief Business Officer of Axovant Gene Therapies.

Dr. Ramaswamy received his MD from Brown University and his undergraduate degree in economics from Harvard University.

Fraser Wright is the Scientific Co-Founder and Chief Scientific Advisor at Kriya Therapeutics. Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. He was also the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia. He was also previously the director of development and clinical manufacturing at Avigen.

Dr. Wright received his PhD in biochemistry and molecular immunology and his undergraduate degree in biochemistry and physiology from the University of Toronto.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. More information is available at www.ArvelleTx.com.

Lily Nguyen is the Chief of Staff at Kriya Therapeutics. Ms. Nguyen joins Kriya from SpringWorks, a company focused on advancing therapies in rare disease and oncology, where she was Director of Program and Alliance Management. She supported development teams to plan and execute global clinical studies and managed development programs with alliance partners. Prior to SpringWorks, Ms. Nguyen was Senior Director of Program Management at Roivant Sciences where she led planning and organization of drug development projects through NDA preparation and coordination of due diligence reviews for potential in-license assets. She has over 15 years of drug development experience and has held project management roles of increasing responsibility at Aerie, Cempra, and Synthon Pharmaceuticals.

Ms. Nguyen received her MBA from the University of North Carolina at Chapel Hill and her undergraduate degree in chemical engineering at North Carolina State University.

Ma'an Muhsin is the President & Chief Medical Officer at Kriya Therapeutics. Ma'an Muhsin attended School of Medicine.

Nachi Gupta is the President of Technologies at Kriya Therapeutics. Dr. Gupta is board-certified in emergency medicine. Prior to his career as a clinician, Dr. Gupta was a quantitative analyst at Brevan Howard Asset Management. He also previously held an associate staff position at MIT Lincoln Laboratories on the ballistic missile defense team. Dr. Gupta received his MD from Brown University and completed his residency in emergency medicine at Mount Sinai Hospital in New York City. He also received his Ph.D. in mathematics from Oxford University. Dr. Gupta holds advanced degrees in computer science and mathematics as well as undergraduate degrees in economics and engineering from the University of Pennsylvania.

Britt Petty is the Chief Manufacturing Officer at Kriya Therapeutics. Mr. Petty joined Kriya from AveXis, a Novartis company, focused on the development and commercialization of gene therapies for neurological genetic diseases, where he was the Chief Technical Officer (interim) and Head of Global Manufacturing. At AveXis, he was responsible for manufacturing the company’s commercial and clinical gene therapy products at both internal and external sites across the United States and Europe. Mr. Petty oversaw all of supply chain, engineering, program management, and manufacturing science and technology functions. Prior to AveXis, Mr. Petty held senior manufacturing roles at Biogen, including as the site head for the company’s North Carolina facility. He previously held manufacturing roles of increasing responsibility at Amgen and Eli Lily and Co.

Mr. Petty received his MBA from the University of North Carolina at Chapel Hill and his undergraduate degree in mechanical engineering at Rose-Hulman Institute of Technology.

Shankar Ramaswamy is the Co-Founder, Chairman, and Chief Executive Officer of Kriya Therapeutics. Dr. Ramaswamy was part of the early foundational team at Roivant Sciences, where he was responsible for helping to identify and evaluate assets across therapeutic areas and launch its first public subsidiary company. He went on to be the Chief Business Officer of Axovant Gene Therapies.

Dr. Ramaswamy received his MD from Brown University and his undergraduate degree in economics from Harvard University.

Fraser Wright is the Scientific Co-Founder and Chief Scientific Advisor at Kriya Therapeutics. Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. He was also the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia. He was also previously the director of development and clinical manufacturing at Avigen.

Dr. Wright received his PhD in biochemistry and molecular immunology and his undergraduate degree in biochemistry and physiology from the University of Toronto.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. More information is available at www.ArvelleTx.com.

Fraser Wright is the Scientific Co-Founder and Chief Scientific Advisor at Kriya Therapeutics. Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. He was also the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia. He was also previously the director of development and clinical manufacturing at Avigen.

Dr. Wright received his PhD in biochemistry and molecular immunology and his undergraduate degree in biochemistry and physiology from the University of Toronto.